Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Observer-blind, Multi-center, Noninferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Trivalent Inactivated Split-Virion Influenza Vaccine in a Pediatric Population Aged Greater Than or Equal to 6 Months to Less Than 18 Years.

NCT00959049 is registered in ClinicalTrials.gov with Seqirus as lead sponsor.

NCT NCT00959049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00959049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Observer-blind, Multi-center, Noninferiority Comparison of the Immune Response of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Trivalent Inactivated Split-Virion Influenza Vaccine in a Pediatric Population Aged Greater Than or Equal to 6 Months to Less Than 18 Years.
Lead sponsor
Seqirus
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2009
Completion date
May 31, 2010
Enrollment
1,474 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

influenza